Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Rexin-G Controls Tumor Growth And Improves Survival In Chemotherapy-Resistant Sarcoma And Osteosarcoma: Phase I/II And Phase II Studies, ASCO 2009
Epeius Biotechnologies announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S. The Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic bone and soft tissue sarcomas (ASCO Annual Meeting 2009, #10513) demonstrated that Rexin-G was well-tolerated with no dose-limiting toxicity. Moreover, Rexin-G exhibited dose-dependent efficacy in terms of tumor control rates, progression-free survival, and overall survival, thus validating both the efficiency of the tumor-targeting technology and the pharmacological mechanisms of action.
generic viagra online
Achaogen Data Show Rapid Rise In Rates Of Resistance To Current Antibiotics
Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today the presentation of research on aminoglycoside (AG) resistance trends and comparative AG toxicities at the 19th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held May 16-19, 2009 in Helsinki, Finland.
News of the day
Uphill Battle For Obama Sparks Comparisons To Clinton's Failed Reform Bid
"Will failing to reform health care have the same consequences for Obama"s administration as it did for Clinton"s?" CNN asks.
Sexual Health

Interactive Medica Launches Pharmaceutical Key Account Management SaaS Solution

Interactive Medica, the leading Pharma SaaS provider, today launches IM Strategic Selling, a new Software as a Service (SaaS) solution that enables promotional teams, managers and executives to identify, collaborate, plan and manage goals, strategies and activities for current and potential Key Accounts. The changing healthcare environment that Pharmaceutical companies face today is radically different from years gone by, companies who do not embrace the more collaborative, many to many, selling approach may find themselves left out of the key relationships required to sustain the use of their products. Being able to implement and manage a Key Account Plan is a pre-requisite for any Pharmaceutical company needing to communicate with multiple decision makers and stakeholders within the Health Service. "Many of the Pharmaceutical companies that Interactive Medica works with are looking at a Key Account Management approach but are put off by how complex it can appear, we felt that we could use our expertise to create a solution that makes this new sales approach far simpler. IM Strategic Selling supports this new complex method of selling by providing a wizard that helps and guides the sales team through this process making it far simpler to identify key actions or issues that need addressing." "IM Strategic Selling is platform independent allowing it to be used in conjunction with Pharmaceutical companies existing CRM and sales support applications enabling any Pharmaceutical sales team to benefit from the solution quickly and easily." "IM Strategic Selling allows our clients to co-ordinate a key account plan enabling them to orchestrate and allocate company res as efficiently as possible. Using IM Strategic Selling, our clients" account teams become focused on the overall opportunity, the relationships and res required to strategically expand the account." "Miller Heiman"s strategic selling model is one example of a business process that IM Strategic Selling is supporting however, we appreciate that every Pharmaceutical company is different and will adopt the specific model that fits their strategy. With IM Strategic Selling clients will be able to tailor the application to meet their exact business processes. " "We are very excited by IM Strategic Selling and the possibilities it can present to Pharmaceutical companies. " comments Richard Jenkinson, CEO of Interactive Medica. Database subscription RealWire aims to provide a targeted distribution through our RealWire service to editorial contacts. If you feel that releases received have not been well targeted and relevant to your areas of interest, please let us know and we will work to ensure this is corrected. If you wish to be unsubscribed, please reply to this release email and we will remove you immediately. Interactive Medica


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009